A private debt placement involving 13 investors has pulled in $5.1 million for Respicardia, bringing the company closer to its target of $6.6 million. The company, which makes the implantable Remede System for treating central sleep apnea, recently found positive results in a trial, which showed 51% of patients achieved a reduction in the number of sleep apnea events per hour.
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.